Literature DB >> 35400826

A questionnaire-based survey on the etiopathogenesis of chronic constipation during a medical check-up in Japan.

Koji Otani1, Toshio Watanabe2, Kanae Takahashi3, Masaki Ominami1, Yuji Nadatani2, Shusei Fukunaga1, Shuhei Hosomi1, Noriko Kamata1, Fumio Tanaka1, Yasuaki Nagami1, Koichi Taira1, Tatsuo Kimura2, Shinya Fukumoto2, Yasuhiro Fujiwara1.   

Abstract

The study group of the Japanese Society of Gastroenterology released evidence-based clinical practice guidelines for chronic constipation (CC) in 2017, and irritable bowel syndrome (IBS) was treated as one of the causes of CC. We examined the differences in characteristics between IBS and non-IBS subjects with CC who underwent a medical check-up in Japan. A total of 10,658 subjects participated in this study, and we focused on 467 subjects who fulfilled the diagnostic criteria of CC using a questionnaire survey. The number of IBS subjects was 21, and they had sleep disorders, were more symptomatic (e.g., abdominal pain, abdominal bloating/distension, feeling stressed, annoyance, lack of motivation, fatigue upon waking, and feeling depressed), and had more episodes of sensation of incomplete evacuation and anorectal obstruction/blockage during defecation than non-IBS subjects. Furthermore, stool frequency of IBS subjects was significantly different from non-IBS subjects. Multivariate ordinal logistic regression analysis revealed that the factors associated with a higher stool frequency were IBS [odds ratio (OR), 2.46; 95% confidence interval (CI), 1.00-6.05; p = 0.049], male sex (OR, 1.97; 95% CI, 1.20-3.23; p = 0.007), and regular exercise (OR, 1.80; 95% CI, 1.05-3.07; p = 0.033). These findings suggest that IBS has unique characteristics in subjects with CC.
Copyright © 2022 JCBN.

Entities:  

Keywords:  Rome IV; chronic constipation; irritable bowel syndrome; medical check-up; stool frequency

Year:  2022        PMID: 35400826      PMCID: PMC8921721          DOI: 10.3164/jcbn.21-87

Source DB:  PubMed          Journal:  J Clin Biochem Nutr        ISSN: 0912-0009            Impact factor:   3.114


Introduction

Chronic constipation (CC) is one of the most common symptom-based bowel disorders. However, it cannot be ignored because it not only worsens daily quality of life (QOL) but may also increase the risk of poorer survival of affected individuals.( Several new agents with various mechanisms have recently been introduced for the treatment of CC, and different approaches are necessary depending on the conditions of the patients with CC. Therefore, it is important to accurately understand and clarify the etiopathogenesis of CC. The study group of the Japanese Society of Gastroenterology released evidence-based clinical practice guidelines for CC in 2017.( In the guidelines, CC was defined based on the Rome IV criteria, and “loose stools rarely present without the use of laxatives” and “insufficient criteria for irritable bowel syndrome (IBS)”, both were included in the criteria for diagnosing functional constipation (FC), were excluded from the diagnostic criteria of CC. It means that CC includes FC and other etiologies, such as symptomatic constipation due to underlying diseases, medication-induced constipation, and IBS. Idiopathic constipation, symptomatic constipation, and medication-induced constipation were classified as slow transit constipation by the American Gastroenterological Association.( Although IBS is generally considered to have normal transit, diarrhea-predominant IBS has a fast colonic transit and constipation-predominant IBS has a delayed colonic transit.( In other words, these types of constipation cannot be distinguished by the colon transit time. Therefore, it is reasonable to consider that IBS is one of the causes of CC because IBS is typically accompanied by bowel disorders, including constipation and diarrhea, in clinical practice, and these conditions may not be discrete entities.( Decreased stool frequency and hard stool form usually make patients aware that they are suffering from CC. The Bristol Stool Form Scale (BSFS) divides the stool form into seven categories ranging from lumpy stool (type 1) to watery stool (type 7); it represents a useful guide for the description of stool consistency and shape. In fact, “fewer than three spontaneous bowel movements per week” and “lumpy or hard stools (BSFS type 1 or 2) more than 25% of defecations” are included in the diagnostic criteria of CC, although these items alone are not sufficient to diagnose CC. Based on these findings, we consider that it is necessary to investigate lifestyle habits, underlying diseases including IBS, and medications that are associated with stool frequency and stool form to develop an appropriate therapeutic regimen for patients with CC in consideration of its etiopathogenesis. This study aimed to examine the differences in characteristics between IBS and non-IBS subjects with CC and the factors associated with stool frequency and stool form among subjects with CC who underwent a medical check-up in Japan.

Methods

Study design

This was a single-center, cross-sectional survey of prospective subjects.

Study population

A total of 13,729 subjects underwent a medical check-up at our clinic, MedCity21, that provides medical examination and health screening from the view of preventive medicine between April 2018 and March 2019. All subjects were given a questionnaire inquiring that covered the diagnostic criteria of CC and IBS, and all questionnaires were collected on the day of the medical check-up. A total of 10,658 participants completed the questionnaires with written informed consent (response rate: 77.6%). This study focused on 467 participants who fulfilled the diagnostic criteria for CC. The exclusion criteria were subjects who refused to participate in this study and those judged as inappropriate by the principal investigator. The clinical data of the subjects were obtained from their medical records and general questionnaires during a medical check-up.

Questionnaire

The questionnaire inquired about seven levels of stool frequency (less than once in 3 days, once in 3 days, once in 2 days, once a day, twice a day, three times a day, or more than 4 times a day), seven types of stool form based on BSFS [separate hard lumps (type 1), sausage-shaped but lumpy (type 2), like a sausage with cracks on the surface (type 3), like a sausage or snake, smooth and soft (type 4), soft blobs with clear-cut edges (type 5), fluffy pieces with ragged edges, a mushy stool (type 6), or watery, no solid pieces, entirely liquid (type 7)], defecation situation [straining during more than one-fourth of defecation episodes, lumpy or hard stools (BSFS type 1 or 2) during more than one-fourth of defecation episodes, sensation of incomplete evacuation during more than one-fourth of defecation episodes, sensation of anorectal obstruction/blockage during more than one-fourth of defecation episodes, manual maneuvers to facilitate defecation during more than one-fourth of defecation episodes, fewer than three spontaneous bowel movements per week, and above symptoms present for the last 3 months with symptom onset at least 6 months prior], and abdominal pain occurring, on average, at least 1 day per week for the last 3 months [abdominal pain related to defecation, abdominal pain associated with a change in stool frequency, abdominal pain associated with a change in stool form (appearance), and above symptoms present for the last 3 months with symptom onset at least 6 months prior].

Diagnosis of CC and IBS

CC was diagnosed according to the Japanese evidence-based clinical practice guidelines for chronic constipation in 2017 based on the Rome IV criteria as follows: 1) presence of more than two of the following: straining during more than one-fourth of defecation episodes, lumpy or hard stools (BSFS type 1 or 2) during more than one-fourth of defecation episodes, sensation of incomplete evacuation during more than one-fourth of defecation episodes, sensation of anorectal obstruction/blockage during more than one-fourth of defecation episodes, manual maneuvers to facilitate defecation during more than one-fourth of defecation episodes, and fewer than three spontaneous bowel movements per week, and 2) fulfillment of the criteria for the last 3 months with symptom onset at least 6 months prior. IBS was diagnosed based on the Rome IV criteria as follows: 1) recurrent abdominal pain occurring, on average, at least 1 day per week for the last 3 months and associated with more than two of the following: abdominal pain related to defecation, abdominal pain associated with a change in stool frequency, abdominal pain associated with a change in stool form (appearance), and 2) fulfillment of the criteria for the last 3 months with symptom onset at least 6 months prior. IBS with predominant constipation or mixed bowel habits (IBS-C/M) was defined as IBS with lumpy or hard stools (BSFS type 1 or 2) during more than one-fourth of defecation episodes.

Outcome measurement

The primary aim of this study was to examine the clinical characteristics of subjects with CC and the factors associated with stool frequency and stool form among subjects with CC based on the data from a medical check-up.

Ethical approval

The study protocol was approved by the ethics committee of the Osaka City University Graduate School of Medicine (No. 3928) on December 27, 2017. Written informed consent was obtained from each subject included in the study. We disclosed information about this study on the webpage of the institution, and the subjects had the opportunity to opt out. The study was conducted in accordance with the Declaration of Helsinki ethical principles for medical research involving human subjects.

Statistical analysis

Data are expressed as median and interquartile range for continuous variables and as numbers and percentage for categorical variables. Continuous variables were compared using the Mann–Whitney U test, and categorical variables were compared using Pearson’s chi–square test or Fisher’s exact test. Clinical factors associated with stool frequency and stool form were analyzed using proportional odds ordinal logistic regression analysis, and the odds ratio (OR) and 95% confidence interval (CI) were estimated for each factor. Statistical calculations and analyses were performed using IBM SPSS Statistics ver. 26 (IBM Corporation, Armonk, NY) or R software, ver. 4.0.0 (The R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was set at p<0.05.

Results

Baseline characteristics of subjects with CC

The median age of a total of 10,658 subjects was 51.0 (range, 43.0–60.0), 5,047 subjects (47.4%) were men, and their median body mass index (BMI) was 22.3 (range, 20.2–24.7). The median age of the 467 subjects who fulfilled the diagnostic criteria of CC was 49.0 (range, 42.0–57.0) years, 92 (19.7%) subjects were men, and their median BMI was 21.2 (range, 19.4–23.8) kg/m2. Among the 467 subjects with CC, the number of subjects who fulfilled the diagnostic criteria of IBS was 21 (4.5%). Among these 21 IBS subjects, 16 (76.2%) met the diagnostic criteria for IBS-C/M. IBS subjects had less time of sleep (p = 0.013), insufficient rest by sleep (p = 0.012), and more complaints of abdominal bloating/distension, feeling stressed, annoyance, lack of motivation, fatigue upon waking, and feeling depressed, compared with non-IBS subjects (52.4% vs 22.0%; p = 0.003; 57.1% vs 29.1%; p = 0.005; 38.1% vs 17.5%; p = 0.038; 33.3% vs 10.5%; p = 0.007; 47.6% vs 23.8%; p = 0.014; 28.6% vs 10.3%; p = 0.024, respectively). Furthermore, IBS subjects had a higher Helicobacter pylori (H. pylori) eradication history than non-IBS subjects (33.3% vs 13.9%; p = 0.024) (Table 1).
Table 1.

Baseline characteristics of subjects with chronic constipation

VariablesAll subjectsCCCCp value (IBS vs non-IBS)
IBSNon-IBS
Number of cases10,65846721446
Age (years, median [IQR])51.0 [43.0–60.0]49.0 [42.0–57.0]49.0 [43.0–55.0]49.0 [42.0–57.0]0.584
Age group0.538
 <30148 (1.4%)6 (1.3%)1 (4.8%)5 (1.1%)
 30–391,343 (12.6%)63 (13.5%)4 (19.0%)59 (13.2%)
 40–493,372 (31.6%)172 (36.8%)7 (33.3%)165 (37.0%)
 50–593,116 (29.2%)131 (28.1%)6 (28.6%)125 (28.0%)
 60–691,964 (18.4%)71 (15.2%)2 (9.5%)69 (15.5%)
 ≥70715 (6.7%)24 (5.1%)1 (4.8%)23 (5.2%)
Sex1
 Male5,047 (47.4%)92 (19.7%)4 (19.0%)88 (19.7%)
 Female5,611 (52.6%)375 (80.3%)17 (81.0%)358 (80.3%)
BMI (kg/m2, median [IQR])22.3 [20.2–24.7]21.2 [19.4–23.8]20.4 [18.4–22.9]21.2 [19.5–23.8]0.2
Alcohol intake (≥5 days a week)2,726 (25.6%)55 (11.8%)3 (14.3%)52 (11.7%)0.726
Daily drinking quantity0.245
 <1 go (180 ml of Japanese sake)6,706 (62.9%)356 (76.2%)15 (71.4%)341 (76.5%)
 ≥1 and <2 go1,782 (16.7%)61 (13.1%)2 (9.5%)59 (13.2%)
 ≥2 and <3 go1,525 (14.3%)37 (7.9%)2 (9.5%)35 (7.8%)
 ≥3 go586 (5.5%)13 (2.8%)2 (9.5%)11 (2.5%)
Smoking habit (current smoker)1,566 (14.7%)57 (12.2%)2 (9.5%)55 (12.3%)1
Exercise for ≥30 min at least twice a week for ≥1 year2,638 (24.8%)63 (13.5%)5 (23.8%)58 (13.0%)0.183
Walking (or an equal amount of exercise) for ≥1 h a day4,399 (41.3%)160 (34.3%)9 (42.9%)151 (33.9%)0.481
Walking faster than other people of the same age and sex5,536 (51.9%)217 (46.5%)10 (47.6%)207 (46.4%)1
Sleep for ≥6 h a day7,022 (65.9%)260 (55.7%)6 (28.6%)254 (57.0%)0.013
Getting enough rest by sleeping6,216 (58.3%)220 (47.1%)4 (19.0%)216 (48.4%)0.012
Skipping breakfast ≥3 times a week1,519 (14.3%)82 (17.6%)5 (23.8%)77 (17.3%)0.391
Eating 2 h before going to bed ≥3 times a week2,960 (27.8%)134 (28.7%)8 (38.1%)126 (28.3%)0.331
Eating snacks and sweet drinks in addition to three meals in a day8,442 (79.2%)415 (88.9%)17 (81.0%)398 (89.2%)0.275
Eating faster than other people4,137 (38.8%)188 (40.3%)9 (42.9%)179 (40.1%)0.823
Weight gain of ≥10 kg from the age of 203,712 (34.8%)136 (29.1%)4 (19.0%)132 (29.6%)0.461
State of biting and eating a meal0.619
Can bite and eat anything9,083 (85.2%)373 (79.9%)16 (76.2%)357 (80.0%)
Feel difficulty in biting due to teeth problems1,470 (13.8%)92 (19.7%)5 (23.8%)87 (19.5%)
Hardly bite47 (0.4%)2 (0.4%)0 (0.0%)2 (0.4%)
Lifestyle improvement0.473
Already improving2,686 (25.2%)91 (19.5%)2 (9.5%)89 (20.0%)
Willing to improve5,852 (54.9%)295 (63.2%)16 (76.2%)279 (62.6%)
No intention to improve2,062 (19.3%)81 (17.3%)3 (14.3%)78 (17.5%)
Willing to use opportunity to receive health instruction on lifestyle improvement5,111 (48.0%)229 (49.0%)13 (61.9%)216 (48.4%)0.268
Heartburn481 (4.5%)28 (6.0%)0 (0.0%)28 (6.3%)0.62
Nausea151 (1.4%)13 (2.8%)2 (9.5%)11 (2.5%)0.099
Stomachache631 (5.9%)48 (10.3%)5 (23.8%)43 (9.6%)0.057
Abdominal bloating/distension812 (7.6%)109 (23.3%)11 (52.4%)98 (22.0%)0.003
Feeling stressed2,244 (21.1%)142 (30.4%)12 (57.1%)130 (29.1%)0.005
Annoyance1,129 (10.6%)86 (18.4%)8 (38.1%)78 (17.5%)0.038
Lack of motivation662 (6.2%)54 (11.6%)7 (33.3%)47 (10.5%)0.007
Fatigue upon waking1,604 (15.0%)116 (24.8%)10 (47.6%)106 (23.8%)0.014
Feeling depressed726 (6.8%)52 (11.1%)6 (28.6%)46 (10.3%)0.024
General disinterest239 (2.2%)19 (4.1%)1 (4.8%)18 (4.0%)0.566
H. pylori eradication history1,567 (14.7%)69 (14.8%)7 (33.3%)62 (13.9%)0.024
Fecal occult blood test -positive989 (9.3%)62 (13.3%)2 (9.5%)60 (13.5%)0.751
History of colorectal polyps782 (7.3%)43 (9.2%)0 (0.0%)43 (9.6%)0.243
History of colorectal cancer88 (0.8%)1 (0.2%)0 (0.0%)1 (0.2%)1
History of cardiovascular diseases328 (3.1%)15 (3.2%)1 (4.8%)14 (3.1%)0.504
History of cerebrovascular diseases178 (1.7%)14 (3.0%)1 (4.8%)13 (2.9%)0.48
Chronic kidney disease (Stage G3a–G5)1,033 (9.7%)38 (8.1%)0 (0.0%)38 (8.5%)0.241
Antihypertensive drugs1,513 (14.2%)55 (11.8%)1 (4.8%)54 (12.1%)0.493
Hypoglycemic drugs or insulin391 (3.7%)21 (4.5%)0 (0.0%)21 (4.7%)0.615
Antidyslipidemic drugs1,210 (11.4%)59 (12.6%)1 (4.8%)58 (13.0%)0.497
Levothyroxine sodium hydrate133 (1.2%)7 (1.5%)1 (4.8%)6 (1.3%)0.277
Antihistaminc drugs254 (2.4%)12 (2.6%)2 (9.5%)10 (2.2%)0.097
Antipsychotics or antidepressants115 (1.1%)7 (1.5%)0 (0.0%)7 (1.6%)1
Anxiolytics or sleeping pills230 (2.2%)18 (3.9%)1 (4.8%)17 (3.8%)0.57
Iron supplements34 (0.3%)3 (0.6%)0 (0.0%)3 (0.7%)1
Acid secretion suppressants394 (3.7%)21 (4.5%)0 (0.0%)21 (4.7%)0.615
Laxatives135 (1.3%)21 (4.5%)1 (4.8%)20 (4.5%)1

CC, chronic constipation; IBS, irritable bowel syndrome; IQR, interquartile range; BMI, body mass index; H. pylori, Helicobacter pylori. One go of Japanese sake contains approximately 22 g of ethanol.

Stool frequency and stool form, defecation situation, and abdominal pain based on questionnaire responses

The most common average stool frequency and stool form among all subjects were once a day (51.3%) and type 4 (like a sausage or snake, smooth and soft) (62.9%), respectively. The most common average stool frequency and stool form among all subjects with CC were once in 3 days (35.1%) and type 2 (sausage-shaped but lumpy) (27.0%), respectively. There was a significant deviation in stool frequency between IBS subjects and non-IBS subjects (p = 0.009). However, the stool form based on the BSFS was not significantly different between the two groups (p = 0.170). In defecation situations, IBS subjects had more episodes of sensation of incomplete evacuation and sensation of anorectal obstruction/blockage during defecation (90.5% vs 64.1%; p = 0.017 and 57.1% vs 30.7%; p = 0.016, respectively) (Table 2).
Table 2.

Stool frequency and stool form, defecation situation, and abdominal pain based on questionnaire responses

VariablesAll subjectsCCCCp value (IBS vs non-IBS)
IBSNon-IBS
Stool frequency0.009
 Less than once in 3 days280 (2.6%)137 (29.3%)4 (19.0%)133 (29.8%)
 Once in 3 days655 (6.1%)164 (35.1%)6 (28.6%)158 (35.4%)
 Once in 2 days1,593 (14.9%)111 (23.8%)5 (23.8%)106 (23.8%)
 Once a day5,470 (51.3%)42 (9.0%)2 (9.5%)40 (9.0%)
 Twice a day1,860 (17.5%)6 (1.3%)2 (9.5%)4 (0.9%)
 Three times a day551 (5.2%)3 (0.6%)1 (4.8%)2 (0.4%)
 More than 4 times a day193 (1.8%)3 (0.6%)1 (4.8%)2 (0.4%)
Stool form based on BSFS0.17
 Type 1329 (3.1%)125 (26.8%)3 (14.3%)122 (27.4%)
 Type 2350 (3.3%)126 (27.0%)6 (28.6%)120 (26.9%)
 Type 31,335 (12.5%)121 (25.9%)6 (28.6%)115 (25.8%)
 Type 46,706 (62.9%)59 (12.6%)2 (9.5%)57 (12.8%)
 Type 51,546 (14.5%)24 (5.1%)2 (9.5%)22 (4.9%)
 Type 6307 (2.9%)9 (1.9%)2 (9.5%)7 (1.6%)
 Type 721 (0.2%)1 (0.2%)0 (0.0%)1 (0.2%)
Defecation situation
 Straining during ≥one-fourth of defecation episodes1,700 (16.0%)275 (58.9%)14 (66.7%)261 (58.5%)0.505
 Lumpy or hard stools during ≥one-fourth of defecation episodes2,096 (19.7%)366 (78.4%)16 (76.2%)350 (78.5%)0.788
Sensation of incomplete evacuation during ≥one-fourth of defecation episodes2,694 (25.3%)305 (65.3%)19 (90.5%)286 (64.1%)0.017
Sensation of anorectal obstruction/blockage during ≥one-fourth of defecation episodes572 (5.4%)149 (31.9%)12 (57.1%)137 (30.7%)0.016
Manual maneuvers to facilitate defecation during ≥one-fourth of defecation episodes304 (2.9%)79 (16.9%)4 (19.0%)75 (16.8%)0.767
Fewer than three spontaneous bowel movements per week1,093 (10.3%)316 (67.7%)13 (61.9%)303 (67.9%)0.634
Above symptoms present for the last 3 months with symptom onset at least 6 months prior598 (5.6%)467 (100.0%)21 (100.0%)446 (100.0%)NA
Abdominal pain occurring, on average, at least 1 day per week for the last 3 months
Abdominal pain related to defecation1,868 (17.5%)148 (31.7%)21 (100.0%)127 (28.5%)<0.001
Abdominal pain associated with a change in stool frequency646 (6.1%)81 (17.3%)17 (81.0%)64 (14.3%)<0.001
Abdominal pain associated with a change in stool form (appearance)935 (8.8%)67 (14.3%)14 (66.7%)53 (11.9%)<0.001
Above symptoms present for the last 3 months with symptom onset at least 6 months prior156 (1.5%)34 (7.3%)21 (100.0%)13 (2.9%)<0.001

CC, chronic constipation; IBS, irritable bowel syndrome; BSFS, Bristol Stool Form Scale; NA, not applicable.

Multivariate ordinal logistic regression analysis of factors associated with a higher stool frequency or a looser stool form among subjects with CC

Multivariate ordinal logistic regression analysis revealed that the factors associated with a higher stool frequency among CC patients were male sex (OR, 1.97; 95% CI, 1.20–3.23; p = 0.007), exercise for more than 30 min at least twice a week for more than 1 year (OR, 1.80; 95% CI, 1.05–3.07; p = 0.033), and presence of IBS (OR, 2.46; 95% CI, 1.00–6.05; p = 0.049). On the other hand, factors associated with a looser stool form were male sex (OR, 2.47; 95% CI, 1.50–4.06; p<0.001), current smoking (OR, 2.36; 95% CI, 1.38–4.03; p = 0.002), and exercise for more than 30 min at least twice a week for more than 1 year (OR, 1.83; 95% CI, 1.08–3.08; p = 0.024) (Table 3).
Table 3.

Multivariate ordinal logistic regression analysis of factors associated with a higher stool frequency or a looser stool form among subjects with chronic constipation

VariablesHigher stool frequencyLooser stool form
OR (95% CI)p valueOR (95% CI)p value
Age1.02 (1.00–1.04)0.1180.99 (0.97–1.00)0.123
Male sex (reference: female sex)1.97 (1.20–3.23)0.0072.47 (1.50–4.06)<0.001
BMI1.02 (0.95–1.08)0.6381.05 (0.99–1.12)0.107
Alcohol intake (≥5 days a week)1.14 (0.64–2.01)0.6611.22 (0.70–2.13)0.482
Smoking habit (current smoker)0.88 (0.52–1.49)0.6212.36 (1.38–4.03)0.002
Exercise for ≥30 min at least twice a week for ≥1 year1.80 (1.05–3.07)0.0331.83 (1.08–3.08)0.024
Walking (or an equal amount of exercise) for ≥1 h a day0.94 (0.64–1.39)0.7530.83 (0.56–1.21)0.323
Walking faster than other people of the same age and sex1.20 (0.84–1.71)0.3130.79 (0.56–1.12)0.19
Getting enough rest by sleeping0.99 (0.70–1.40)0.9510.91 (0.64–1.29)0.595
Skipping breakfast ≥3 times a week0.92 (0.57–1.48)0.7320.93 (0.58–1.48)0.757
Eating 2 h before going to bed ≥3 times a week1.02 (0.69–1.52)0.9241.43 (0.96–2.14)0.081
Eating snacks and sweet drinks in addition to three meals in a day1.22 (0.67–2.22)0.5160.74 (0.40–1.37)0.338
Eating faster than other people0.81 (0.57–1.16)0.2491.00 (0.71–1.42)0.987
Weight gain of ≥10 kg from the age of 201.14 (0.71–1.85)0.5860.72 (0.45–1.16)0.175
IBS2.46 (1.00–6.05)0.0491.69 (0.74–3.89)0.214
H. pylori eradication history1.28 (0.76–2.15)0.3591.45 (0.88–2.40)0.148
History of cardiovascular diseases1.40 (0.49–4.00)0.5260.86 (0.33–2.30)0.769
History of cerebrovascular diseases1.32 (0.44–3.92)0.6231.38 (0.48–3.92)0.551
Chronic kidney disease (Stage G3a–G5)0.70 (0.35–1.40)0.3131.83 (0.94–3.56)0.076
Antihypertensive drugs1.28 (0.65–2.55)0.4781.22 (0.62–2.41)0.571
Hypoglycemic drugs or insulin0.44 (0.17–1.20)0.1090.68 (0.27–1.74)0.417
Antidyslipidemic drugs1.06 (0.54–2.07)0.870.81 (0.45–1.47)0.489
Levothyroxine sodium hydrate0.53 (0.13–2.23)0.3870.91 (0.23–3.50)0.885
Antipsychotics or antidepressants1.46 (0.37–5.76)0.5880.81 (0.20–3.24)0.768
Anxiolytics or sleeping pills0.72 (0.29–1.81)0.4810.44 (0.16–1.18)0.103
Iron supplements0.25 (0.02–2.67)0.2510.75 (0.11–5.23)0.775

OR, odds ratio; CI, confidence interval; BMI, body mass index; IBS, irritable bowel syndrome; H. pylori, Helicobacter pylori.

Discussion

We conducted this study to examine the difference in characteristics of subjects who met the criteria for CC by dividing the subjects into IBS and non-IBS. Our results showed that IBS subjects with CC had sleep disorders, complex symptoms, dyschezia sensation, and higher stool frequency among subjects with CC. We found that the proportion of IBS subjects was 4.5% among the subjects with CC. The prevalence of IBS in our study was lower than a previous report that the prevalence of IBS diagnosed by the Rome III criteria among the subjects with CC diagnosed by the modified Rome III criteria was 17%.( It is reported that the prevalence of IBS diagnosed by the Rome IV criteria is generally lower than that diagnosed by the Rome III criteria in a systematic review and meta-analysis.( Moreover, the prevalence of CC can widely range from 0.7% to 79% depending on the definition used and population studied,( and there are few reports about the prevalence of CC diagnosed by the Japanese evidence-based clinical practice guidelines for chronic constipation in 2017. A low prevalence of IBS in our study may be attributed to these reasons. The pathophysiology of IBS is heterogeneous, and various factors seem to be involved, such as abnormal gastrointestinal motility, visceral hypersensitivity, disturbances in brain–gut interaction, psychosocial distress, and altered gut microbiome.( IBS is typically accompanied by other functional disorders, such as constipation and diarrhea, due to abnormal gastrointestinal motility.( Moreover, the proportion of subjects with IBS-C/M was 76.2% among the IBS subjects with CC, indicating that IBS subjects with CC did not always have a stiff stool form. Of note, IBS subjects had significantly less time of sleep and insufficient rest by sleep among their lifestyle habits. This is consistent with previous reports that have shown that the prevalence of sleep disorder is higher in IBS patients,( which may be because sleep disorders are associated with dysregulation of the autonomic nervous system that causes IBS.( Abdominal pain, a component of the diagnostic criteria of IBS, and abdominal bloating/distension were more common in IBS patients, which might be due to the abnormal visceral hypersensitivity and disturbances in brain–gut interaction. In addition to abdominal pain and abdominal bloating/distension, troublesome symptoms of daily life, such as feeling stressed, annoyance, lack of motivation, fatigue upon waking, feeling depressed, were significantly more common in IBS subjects than in non-IBS subjects. It is known that psychological and psychiatric comorbidities, such as anxiety, depression, and paranoia, are common among IBS patients.( Therefore, these symptoms may result from psychosocial distress and psychiatric comorbidities in IBS patients. Kawamura et al.( reported that IBS subjects with predominant constipation complained of more severe symptoms than FC subjects, resulting in impairment of QOL. Furthermore, IBS subjects had more H. pylori eradication histories than non-IBS subjects. As there are reports that H. pylori infection is involved in triggering visceral hypersensitivity in IBS patients( and H. pylori eradication treatment alters gut microbiota that is closely related to gastrointestinal health status,( there may be some association between H. pylori and IBS. In defecation situations, IBS subjects had significantly more episodes of sensation of incomplete evacuation and sensation of anorectal obstruction/blockage during defecation. These sensations may be due to the hypersensitivity of rectum and anus. Multivariate ordinal logistic regression analysis revealed that male sex, exercise for more than 30 min at least twice a week for more than 1 year, and IBS were independently associated with a higher stool frequency among subjects with CC. As more IBS subjects complained of abdominal pain associated with a change in stool frequency and sensation of difficulty during defecation, these uncomfortable symptoms might have increased the stool frequency in patients with IBS even if they were experiencing CC. On the other hand, looser stool form was associated with male sex, current smoking status, and exercise for more than 30 min at least twice a week for more than 1 year. Nicotine binds to nicotinic acetylcholine receptors to stimulate parasympathetic nerves and interferes with water absorption, resulting in a looser stool form.( Exercise for more than 30 min at least twice a week for more than 1 year was significantly associated with both higher stool frequency and looser stool form among subjects with CC. It has been reported that regular exercise with moderate physical activity shortens the intestinal transit time and reduce the risk of constipation.( Regular exercise habits or medication therapy, such as osmotic laxatives, stimulant laxatives, chloride channel activators, guanylate cyclase activators, and 5-hydroxytryptamine receptor 4 agonists, may be helpful to relieve constipation symptoms for CC patients. When treating IBS patients with CC, more multi-faceted therapeutic approach will be necessary. The effects of chloride channel activators and guanylate cyclase activators on those patients have been proven in a systematic review and meta-analysis,( and the use of these drugs are recommended in the American College of Gastroenterology clinical guidelines.( Sleeping pills, anxiolytics, and antidepressants will be effective for their sleep disorders, anxiety, and depressive symptoms.( Moreover, gut-directed psychotherapy, including cognitive-behavior therapy, hypnotherapy, mindfulness treatment, and stress management is suggested to restore their mental health.( This study has some limitations. First, it was conducted at a single medical check-up institution, and the characteristics of the subjects might have been biased. The subjects who underwent a medical check-up were highly conscious of their health, and their overall health status was generally good. Moreover, very elderly and very young individuals usually do not receive medical check-ups. Second, the questionnaire used in this study was based on self-reported measures by subjects, and issues such as missed reporting and providing inaccurate information were unavoidable. Third, some subjects who did not meet the diagnostic criteria for CC because they took laxatives may meet the criteria for CC if they discontinue the laxatives. It is ideal to assess defecation situation after discontinuing laxatives. However, it is undesirable to discontinue the laxatives just for diagnosing CC. In conclusion, it is suggested that IBS subjects have unique characteristics in subjects with CC as they suffer from sleep disorders, are more symptomatic, have more episodes of sensation of incomplete evacuation and anorectal obstruction/blockage during defecation, and have a higher stool frequency. It is necessary to be aware of these various features of IBS subjects in the treatment of CC, and we hope that these study findings will help to relieve their troublesome symptoms.

Author Contributions

KO designed, analyzed the data, and drafted the paper; TW supervised the study and revised the paper; KTakahashi analyzed the data; MO, YNadatani, SFukunaga, SH, NK, FT, YNagami, KTaira, TK, SFukumoto, and YF reviewed the manuscript and provided valid inputs on the study.
  39 in total

1.  Colonic transit, bowel movements, stool form, and abdominal pain in irritable bowel syndrome by treatments with calcium polycarbophil.

Authors:  Toshimi Chiba; Norihiko Kudara; Masaki Sato; Raita Chishima; Yukito Abiko; Masaaki Inomata; Seishi Orii; Kazuyuki Suzuki
Journal:  Hepatogastroenterology       Date:  2005 Sep-Oct

Review 2.  Irritable Bowel Syndrome: A Clinical Review.

Authors:  Michael D Cashman; Daniel K Martin; Sonu Dhillon; Srinivas R Puli
Journal:  Curr Rheumatol Rev       Date:  2016

3.  Effect of exercise and physical fitness on large intestinal function.

Authors:  S A Bingham; J H Cummings
Journal:  Gastroenterology       Date:  1989-12       Impact factor: 22.682

Review 4.  Irritable bowel syndrome: a clinical review.

Authors:  William D Chey; Jacob Kurlander; Shanti Eswaran
Journal:  JAMA       Date:  2015-03-03       Impact factor: 56.272

Review 5.  Irritable bowel syndrome - from etiopathogenesis to therapy.

Authors:  Biljana Radovanovic-Dinic; Snezana Tesic-Rajkovic; Sasa Grgov; Gordana Petrovic; Valentina Zivkovic
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2018-01-18       Impact factor: 1.245

Review 6.  Review article: epidemiology and quality of life in functional gastrointestinal disorders.

Authors:  L Chang
Journal:  Aliment Pharmacol Ther       Date:  2004-11       Impact factor: 8.171

7.  Impact of functional gastrointestinal disorders on survival in the community.

Authors:  Joseph Y Chang; G Richard Locke; Meredythe A McNally; Smita L Halder; Cathy D Schleck; Alan R Zinsmeister; Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2010-02-16       Impact factor: 10.864

8.  Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis.

Authors:  Priya Oka; Heather Parr; Brigida Barberio; Christopher J Black; Edoardo V Savarino; Alexander C Ford
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-07-20

Review 9.  Role of presynaptic nicotinic acetylcholine receptors in the regulation of gastrointestinal motility.

Authors:  P Mandl; J P Kiss
Journal:  Brain Res Bull       Date:  2007-03-05       Impact factor: 4.077

10.  H. pylori Eradication Treatment Alters Gut Microbiota and GLP-1 Secretion in Humans.

Authors:  Isabel Cornejo-Pareja; Gracia M Martín-Núñez; M Mar Roca-Rodríguez; Fernando Cardona; Leticia Coin-Aragüez; Lidia Sánchez-Alcoholado; Carolina Gutiérrez-Repiso; Araceli Muñoz-Garach; José C Fernández-García; Isabel Moreno-Indias; Francisco J Tinahones
Journal:  J Clin Med       Date:  2019-04-04       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.